Yang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Yang has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Jiapei Yuan
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
25 shared publications - Douglas William Strand
Department of Urology UT Southwestern Medical Center Dallas Texas USA
20 shared publications - GuemHee Baek
Department of Pathology, UT Southwestern Medical Center, Dallas, Texas
20 shared publications - Kathleen E. Houlahan
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
20 shared publications - Michael Q. Zhang
Department of Biological Sciences, Center for Systems Biology, The University of Texas, Richardson, USA
20 shared publications - Paul C. Boutros
Department of Human Genetics, University of California Los Angeles
20 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
Comprehensive Evaluation and Explainable Interpretation of Peptide-HLA Binding Prediction Tools
Accurate prediction of peptide binding to human leukocyte antigen class I (HLA-I) molecules is critical for advancing immunological research, particularly in vaccine design and immunotherapy. However, limitations in model performance, interpretability, and dataset quality impede the widespread adoption of existing predictive tools. Here, we present a comprehensive evaluation of 17 HLA-I peptide binding prediction models, utilizing a meticulously curated dataset comprising over 290,000 peptides spanning 44 HLA-I alleles. We assessed model accuracy, robustness, and interpretability, employing explainability techniques such as SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) to elucidate underlying prediction mechanisms. Our results reveal substantial performance disparities, with self-attention-based models, including STMHCpan and BigMHC, exhibiting superior accuracy. Notably, the capsule network model CapsNet-MHC_AN demonstrated robust performance. Models trained on eluted ligand datasets outperformed those relying on binding affinity data, underscoring the critical role of high-quality training data. Ensemble and multi-algorithm approaches further improved prediction reliability. These findings highlight the need for ongoing innovation in model architecture, integration of diverse and high-quality datasets, and incorporation of structural predictors to develop more accurate, interpretable, and clinically applicable HLA-I peptide binding prediction tools.
- 7 September 2026
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
Open AccessComprehensive Evaluation and Explainable Interpretation of Peptide-HLA Binding Prediction Tools
Accurate prediction of peptide binding to human leukocyte antigen class I (HLA-I) molecules is critical for advancing immunological research, particularly in vaccine design and immunotherapy. However, limitations in model performance, interpretability, and dataset quality impede the widespread adoption of existing predictive tools. Here, we present a comprehensive evaluation of 17 HLA-I peptide binding prediction models, utilizing a meticulously curated dataset comprising over 290,000 peptides spanning 44 HLA-I alleles. We assessed model accuracy, robustness, and interpretability, employing explainability techniques such as SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) to elucidate underlying prediction mechanisms. Our results reveal substantial performance disparities, with self-attention-based models, including STMHCpan and BigMHC, exhibiting superior accuracy. Notably, the capsule network model CapsNet-MHC_AN demonstrated robust performance. Models trained on eluted ligand datasets outperformed those relying on binding affinity data, underscoring the critical role of high-quality training data. Ensemble and multi-algorithm approaches further improved prediction reliability. These findings highlight the need for ongoing innovation in model architecture, integration of diverse and high-quality datasets, and incorporation of structural predictors to develop more accurate, interpretable, and clinically applicable HLA-I peptide binding prediction tools.
- 29 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 619
Using human proteomic and lipidomic to exploration drug target of bladder cancer
Objective The goal of this study is to explore the genetic predictive associations between plasma proteomics and bladder cancer using the Mendelian randomization (MR) method, and to investigate whether plasma lipidomics characteristics mediate these associations. Materials and methods The genome-wide association study (GWAS) data for plasma proteins from deCODE Genetics included 4,907 aptamers for plasma proteins in 35,559 Icelandic individuals. Lipidomic GWAS data of 179 traits (GCST90277238–GCST90277416) were extracted from the GWAS Catalog, and bladder cancer GWAS summary statistics were sourced from FinnGen R8 (2,380 cases and 259,583 controls). Two-sample MR evaluated the causal links between genetically predicted plasma proteins and bladder cancer risk; mediation MR further examined mediating roles of lipidomic. Primary causal analyses adopted the MR Wald ratio and inverse variance-weighted approaches. Heterogeneity was tested by the Cochrane Q test, horizontal pleiotropy by MR-Egger intercept test, and leave-one-out analysis was used for sensitivity assessment. Results and limitations Our findings suggest that genetically predicted levels of 29 proteins may be associated with the risk of bladder cancer. Among these, 17 proteins showed inverse associations with bladder cancer risk, while 12 proteins showed positive associations. A negative mediation proportion indicates that the estimated direction of the indirect effect is opposite to that of the total effect. For example, the mediation proportion of −56% for ETFA suggests that the estimated indirect effect through GCST90277318 is in the opposite direction to the overall association observed between genetically predicted ETFA levels and bladder cancer risk. When ADGRF1 was considered as the exposure and GCST90277318 as the mediator, the estimated proportion mediated was 25%. For NDUFB4 and GCST90277318, the estimated proportion mediated was 20%. For ETFA and GCST90277318, the estimated proportion mediated was −56%, whereas the estimated mediation proportions for most other protein–lipid pairs were approximately 10%.These results reflect putative causal estimates derived from genetic instruments rather than direct causal effects.The findings should be interpreted in light of several limitations, including the use of summary-level data, predominantly European ancestry populations, and the potential bias from lifestyle and clinical confounders,and the need for experimental validation of the identified associations and proposed biological mechanisms. Conclusions This MR study revealed suggestive genetically predicted associations between 29 plasma proteins and bladder cancer risk, and implied that plasma lipidomic traits may partially mediate a subset of these relationships. These observations may shed light on potential molecular mechanisms relevant to bladder cancer and offer candidate proteins for further functional research and therapeutic target verification.
- 29 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 619
Using human proteomic and lipidomic to exploration drug target of bladder cancer
Objective The goal of this study is to explore the genetic predictive associations between plasma proteomics and bladder cancer using the Mendelian randomization (MR) method, and to investigate whether plasma lipidomics characteristics mediate these associations. Materials and methods The genome-wide association study (GWAS) data for plasma proteins from deCODE Genetics included 4,907 aptamers for plasma proteins in 35,559 Icelandic individuals. Lipidomic GWAS data of 179 traits (GCST90277238–GCST90277416) were extracted from the GWAS Catalog, and bladder cancer GWAS summary statistics were sourced from FinnGen R8 (2,380 cases and 259,583 controls). Two-sample MR evaluated the causal links between genetically predicted plasma proteins and bladder cancer risk; mediation MR further examined mediating roles of lipidomic. Primary causal analyses adopted the MR Wald ratio and inverse variance-weighted approaches. Heterogeneity was tested by the Cochrane Q test, horizontal pleiotropy by MR-Egger intercept test, and leave-one-out analysis was used for sensitivity assessment. Results and limitations Our findings suggest that genetically predicted levels of 29 proteins may be associated with the risk of bladder cancer. Among these, 17 proteins showed inverse associations with bladder cancer risk, while 12 proteins showed positive associations. A negative mediation proportion indicates that the estimated direction of the indirect effect is opposite to that of the total effect. For example, the mediation proportion of −56% for ETFA suggests that the estimated indirect effect through GCST90277318 is in the opposite direction to the overall association observed between genetically predicted ETFA levels and bladder cancer risk. When ADGRF1 was considered as the exposure and GCST90277318 as the mediator, the estimated proportion mediated was 25%. For NDUFB4 and GCST90277318, the estimated proportion mediated was 20%. For ETFA and GCST90277318, the estimated proportion mediated was −56%, whereas the estimated mediation proportions for most other protein–lipid pairs were approximately 10%.These results reflect putative causal estimates derived from genetic instruments rather than direct causal effects.The findings should be interpreted in light of several limitations, including the use of summary-level data, predominantly European ancestry populations, and the potential bias from lifestyle and clinical confounders,and the need for experimental validation of the identified associations and proposed biological mechanisms. Conclusions This MR study revealed suggestive genetically predicted associations between 29 plasma proteins and bladder cancer risk, and implied that plasma lipidomic traits may partially mediate a subset of these relationships. These observations may shed light on potential molecular mechanisms relevant to bladder cancer and offer candidate proteins for further functional research and therapeutic target verification.
- Open Access
- 25 July 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Single-cell profiling defines cellular ecosystems and malignant cell state coupling across pan-cancer tumor microenvironments
- 25 July 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Open AccessSingle-cell profiling defines cellular ecosystems and malignant cell state coupling across pan-cancer tumor microenvironments
- Open Access
- 22 May 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 52
Single-cell transcriptomic mapping of immune heterogeneity across angioimmunoblastic T-cell lymphoma subtypes
Relapse and treatment resistance remain critical obstacles in the clinical management of angioimmunoblastic T-cell lymphoma (AITL), limiting the success of
- 22 May 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 52
Open AccessSingle-cell transcriptomic mapping of immune heterogeneity across angioimmunoblastic T-cell lymphoma subtypes
Relapse and treatment resistance remain critical obstacles in the clinical management of angioimmunoblastic T-cell lymphoma (AITL), limiting the success of
- 20 May 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 315, 118982
Targeted degradation of SETDB1 by an Aptamer-CRBNL PROTAC as a novel therapeutic strategy for breast cancer
- 20 May 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 315, 118982
Targeted degradation of SETDB1 by an Aptamer-CRBNL PROTAC as a novel therapeutic strategy for breast cancer
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture
Supplementary Figure from Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture